Showing 3891-3900 of 7373 results for "".
- Vitiligo and Gray Hair Treatment Breakthrough? Study IDs Mechanism That Controls Skin and Hair Colorhttps://practicaldermatology.com/news/vitiligo-and-gray-hair-treatment-breakthrough-study-ids-mechanism-that-controls-skin-and-hair-color/2458587/A pair of molecular signals controls skin and hair color in mice and humans - and could be targeted by new drugs to treat skin pigment disorders like vitiligo, according to a report out of NYU Langone Medical Center in New York City. Finding ways to activate these pathways could lea
- Modernizing Medicine's Dermatology-specific EHR System Top Rated by KLAShttps://practicaldermatology.com/news/modernizing-medicines-dermatology-specific-ehr-system-top-rated-by-klas/2458591/Modernizing Medicine, Inc.’s EMA Dermatology has been rated the top electronic health record (EHR) system for dermatologists in the inaugural KLAS “Ambulatory Specialty 2016 One Size Does Not Fit All Performance Report.” KLAS, best known for its “Best in KLAS: Soft
- Oculus Innovative Sciences' Microcyn®-based Lasercyn™ Gel Cleared for Post-procedure Usehttps://practicaldermatology.com/news/oculus-innovative-sciences-microcyn-based-lasercyn-gel-cleared-for-post-procedure-use/2458597/Oculus Innovative Sciences, Inc. has received a new 510(k) clearance from the FDA for the company's new Microcyn®-based Lasercyn™ Gel. Under the supervision of a healthcare professional, Lasercyn Gel is int
- SCCA Doctors Address the Future of Immunotherapy for Melanomahttps://practicaldermatology.com/news/scca-doctors-address-the-future-of-immunotherapy-for-melanoma/2458600/Immunotherapy is the hottest topic in cancer care today, and metastatic melanoma is among the first type to benefit from this fourth cancer therapy. Two Seattle Cancer Care Alliance (SCC
- Checkpoint Inhibitor Shows Promise in MCChttps://practicaldermatology.com/news/checkpoint-inhibitor-shows-promise-in-mcc/2458603/Advanced Merkel cell carcinoma patients who received KEYTRUDA® (pembrolizumab) showed more durable responses than what is typically seen with standard chemotherapy, according to a study presented at the American Association for Cancer Research Annual Meeting 2016 in New Orleans and simul
- New MRF White Paper Provides Road Map for Eradicating Melanomahttps://practicaldermatology.com/news/new-mrf-white-paper-provides-road-map-for-eradicating-melanoma/2458604/More research needs to be done about what range of wavelengths in the ultraviolet band need to be blocked to prevent melanoma, according to a new white paper from Melanoma Research Foundation (MRF). The paper, "The Stat
- Recent AAD Meeting Boasts Record Attendancehttps://practicaldermatology.com/news/recent-aad-meeting-boasts-record-attendance/2458607/More than 18,500 people from 107 countries attended the American Academy of Dermatology’s 74th Annual Meeting held in Washington, DC in early March 2016. The meeting featured more than 375 educational sessions, during
- AAD Announces New Officers and Board Membershttps://practicaldermatology.com/news/aad-announces-new-officers-and-board-members/2458608/The American Academy of Dermatology (AAD) announced the results of its annual election. These new officers and board members also will hold the same positions for the American Academy of Dermatology Association. Suzanne Olbricht, MD, FAAD will take the office of Academy president-elect. D
- Psoriasis Market Poised for Growth Spurt by 2024https://practicaldermatology.com/news/psoriasis-market-poised-for-growth-spurt-by-2024/2458609/The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a
- Avalere: Biosimilars More Expensive for Medicare Beneficiarieshttps://practicaldermatology.com/news/avalere-biosimilars-more-expensive-for-medicare-beneficiaries/2458610/Medicare beneficiaries are likely to pay more for biosimilars than for the biologic reference product in Part D under current law, according to a new report from